Exclusive | Lilly Agrees to Buys Trio of Vaccine Developers - WSJ
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Eli Lilly agrees to acquire three vaccine developers for nearly $4 billion in deals
- Eli Lilly stock rises modestly after the announcement
Why it matters: Eli Lilly expands its vaccine pipeline with a $4B acquisition spree, prompting a modest stock uptick and increasing competition in the infectious‑disease sector for shareholders and patients alike.
